Inotrem is a clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1 to control unbalanced inflammatory responses.

Inotrem

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

DNSSEC

WordPress

Senior Clinical Project Manager

Anne-Lise Laszlo-Pouvreau

Business Management

Jean-Jacques Garaud

Marc Derive

Co-founder, CSO

Co-Founder, Executive Vice-President, Scientific and Medical Affairs

Margarita Salcedo Magguilli

Chief Development Officer

Martin Koch

Sven Zimmermann

Chief Executive Officer

Roche Alumni Founded Companies

Novartis Alumni Founded Companies

Private France Companies (Top 10K)

Europe Companies With Fewer Than 100 Employees (Top 10K)

Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. 
Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction.

Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

IBD Ventures

Venture Round - Inotrem

Bpifrance

Debt Financing - Inotrem

Kreos Capital

Fountain Healthcare Partners

Series B - Inotrem

Invus

Morningside Venture Investments

Andera Partners

Sofinnova Partners

Series A - Inotrem

Non Equity Assistance - Inotrem

Paris

Ile-de-France

France

Europe

Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock

Sepsis Market to grow significantly by 2032 | La Jolla ...

Inotrem Receives Milestone Funding From the Crohn’s & ...

Blood Conservation System Market Opportunities, Sales ...

Inotrem Receives Milestone Funding From the Crohn's & Colitis Foundation IBD Ventures Program to Advance Its ...

A synthetic peptide and first-in-class TREM-1 inhibitor used to treat acute inflammatory syndromes such as septic shock and severe COVID-19 by restoring a balanced inflammatory response.

A research initiative focused on developing monoclonal antibodies to target chronic inflammatory diseases, fibrotic diseases, and immuno-oncology by inhibiting the TREM-1 pathway.

A diagnostic tool developed in collaboration with Roche Diagnostics to identify septic shock patients who are more likely to benefit from nangibotide treatment by measuring the soluble form of the TREM-1 receptor in blood.

Germany

India

Asia

Spain

HTML5

Lightbox

Wordpress

Wistia

jQuery

GlobalSign

Vimeo

Comodo PositiveSSL Certificates

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 10, 2024 10:07 AM	16c2f2fe
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 10, 2024 10:59 AM	0c00b82d
company summary	general
signals	general	Sep 10, 2024 10:07 AM	3b1442b0
crunchbase trigger	general	Nov 18, 2024 2:12 PM	574fefc0
crunchbase profile	general	Nov 18, 2024 3:45 PM	6a0975f8
li profile	general
translate crunchbase fundingrounds	general	Nov 18, 2024 3:59 PM	616713be
peers	general	Sep 10, 2024 10:07 AM	1e1200a5
news basic	general	Sep 10, 2024 10:07 AM	16026e13
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:INOTREM

Inotrem